Optimal use of aromatase inhibitors: to lead or to follow?
Lin
Nancy U
NU
Winer
Eric P
EP
D000368:Aged; D000483:Alleles; D000077384:Anastrozole; D000970:Antineoplastic Agents / Q000494:pharmacology*; D047072:Aromatase Inhibitors / Q000494:pharmacology*; D001943:Breast Neoplasms / Q000188:drug therapy*; D018572:Disease-Free Survival; D005260:Female; D006801:Humans; D008875:Middle Aged; D009570:Nitriles / Q000494:pharmacology*; D017698:Postmenopause; D011960:Receptors, Estrogen / Q000378:metabolism; D012008:Recurrence; D013629:Tamoxifen / Q000494:pharmacology*; D016896:Treatment Outcome; D014230:Triazoles / Q000494:pharmacology*
D000970:Antineoplastic Agents; D047072:Aromatase Inhibitors; D009570:Nitriles; D011960:Receptors, Estrogen; D014230:Triazoles; D013629:Tamoxifen; D000077384:Anastrozole